Company profile
Ocugen, Inc.
NASDAQ:OCGNBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Brimonidine tartrate | approved | — | 11 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05956626 | phase2_3 | active_not_recruiting | 2023-08-25 | 2026-09-28 | Ocugen | A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease |
| NCT06388200 | phase3 | active_not_recruiting | 2024-06-18 | 2027-02-12 | Ocugen | A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa |
| NCT03418727 | phase2 | completed | 2017-09-06 | 2018-03-29 | Ocugen | Dry Eye Disease Study With Brimonidine |
| NCT05258669 | phase2_3 | unknown | 2022-02-20 | 2023-09-01 | Ocugen | Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults |
| NCT07770828 | phase3 | recruiting | 2026-08-11 | 2028-07-30 | Ocugen | Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD |
FDA applications (0)
No records yet.